The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

The new framework unveiled May 20 says new COVID-19 shots should go only to those ages 65 and up or with underlying medical conditions.

The agency will require manufacturers to conduct randomized, controlled trials to secure approval for healthy Americans.

The change marks a shift in the Food and Drug Administration’s policy on approving COVID-19 vaccines, which the new ...

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.

The FDA announced it will limit access to Covid-19 vaccines going forward to people 65 and older and others at high risk of ...

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

The 25,000-square-foot center is opening with a staff of 35, but that number is expected to double over the next two years.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions — by its April 1 target ...

The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.

The GOP-led House Judiciary Committee is investigating allegations that Pfizer delayed its COVID-19 vaccine testing until ...